Your browser doesn't support javascript.
loading
Schistosomiasis Control: Leave No Age Group Behind.
Faust, Christina L; Osakunor, Derick N M; Downs, Jennifer A; Kayuni, Sekeleghe; Stothard, J Russell; Lamberton, Poppy H L; Reinhard-Rupp, Jutta; Rollinson, David.
Afiliação
  • Faust CL; Wellcome Centre for Integrative Parasitology, Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow G12 8QQ, UK. Electronic address: christina.faust@glasgow.ac.uk.
  • Osakunor DNM; Institute of Immunology and Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, Charlotte Auerbach Road, Edinburgh EH9 3FL, UK.
  • Downs JA; Center for Global Health, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
  • Kayuni S; Department of Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK; MASM Medi Clinics Limited, Medical Aid Society of Malawi (MASM), Blantyre, Malawi.
  • Stothard JR; Department of Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.
  • Lamberton PHL; Wellcome Centre for Integrative Parasitology, Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow G12 8QQ, UK.
  • Reinhard-Rupp J; Merck Global Health Institute, Eysins CH-1262, Switzerland.
  • Rollinson D; Global Schistosomiasis Alliance, Natural History Museum, London SW7 5BD, UK.
Trends Parasitol ; 36(7): 582-591, 2020 07.
Article em En | MEDLINE | ID: mdl-32430274
ABSTRACT
Despite accelerating progress towards schistosomiasis control in sub-Saharan Africa, several age groups have been eclipsed by current treatment and monitoring strategies that mainly focus on school-aged children. As schistosomiasis poses a threat to people of all ages, unfortunate gaps exist in current treatment coverage and associated monitoring efforts, preventing subsequent health benefits to preschool-aged children as well as certain adolescents and adults. Expanding access to younger ages through the forthcoming pediatric praziquantel formulation and improving treatment coverage in older ages is essential. This should occur alongside formal inclusion of these groups in large-scale monitoring and evaluation activities. Current omission of these age groups from treatment and monitoring exacerbates health inequities and has long-term consequences for sustainable schistosomiasis control.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquistossomose Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquistossomose Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2020 Tipo de documento: Article